Publikationen, an denen er mitarbeitet MARÍA DE LA PALOMA BALLESTEROS PAPANTONAKIS (20)

2023

  1. Application of Accelerated Predictive Stability Studies in Extemporaneously Compounded Formulations of Chlorhexidine to Assess the Shelf Life

    Molecules, Vol. 28, Núm. 23

  2. Can amphotericin B and itraconazole be co-delivered orally? Tailoring oral fixed-dose combination coated granules for systemic mycoses

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 183, pp. 74-91

  3. Co-Delivery of a High Dose of Amphotericin B and Itraconazole by Means of a Dry Powder Inhaler Formulation for the Treatment of Severe Fungal Pulmonary Infections

    Pharmaceutics, Vol. 15, Núm. 11

  4. Engineering of 3D printed personalized polypills for the treatment of the metabolic syndrome

    International Journal of Pharmaceutics, Vol. 642

  5. Guiding Clinical Prescription of Topical Extemporaneous Formulations of Sodium Cromoglycate Based on Pharmaceutical Performance

    Pharmaceutics, Vol. 15, Núm. 6

  6. Targeting lung macrophages for fungal and parasitic pulmonary infections with innovative amphotericin B dry powder inhalers

    International journal of pharmaceutics, Vol. 635, pp. 122788

2022

  1. Drug Stability: ICH versus Accelerated Predictive Stability Studies

    Pharmaceutics, Vol. 14, Núm. 11

  2. Self-assembling, supramolecular chemistry and pharmacology of amphotericin B: Poly-aggregates, oligomers and monomers

    Journal of Controlled Release, Vol. 341, pp. 716-732

2020

  1. Oral Fixed-Dose Combination Pharmaceutical Products: Industrial Manufacturing Versus Personalized 3D Printing

    Pharmaceutical Research, Vol. 37, Núm. 7

  2. Personalised 3d printed medicines: Optimising material properties for successful passive diffusion loading of filaments for fused deposition modelling of solid dosage forms

    Pharmaceutics, Vol. 12, Núm. 4

  3. Transferosomes as nanocarriers for drugs across the skin: Quality by design from lab to industrial scale

    International Journal of Pharmaceutics, Vol. 573

  4. Ultradeformable Lipid Vesicles Localize Amphotericin B in the Dermis for the Treatment of Infectious Skin Diseases

    ACS Infectious Diseases, Vol. 6, Núm. 10, pp. 2647-2660

2019

  1. Market demands in 3D printing pharmaceuticals products

    3D Printing Technology in Nanomedicine (Elsevier), pp. 165-183

2017

  1. Analgesic and anti-inflammatory controlled-released injectable microemulsion: Pseudo-ternary phase diagrams, in vitro, ex vivo and in vivo evaluation

    European Journal of Pharmaceutical Sciences, Vol. 101, pp. 220-227

  2. Engineering oral and parenteral amorphous amphotericin B formulations against experimental Trypanosoma cruzi infections

    Molecular Pharmaceutics, Vol. 14, Núm. 4, pp. 1095-1106

  3. Nebulised antibiotherapy: Conventional versus nanotechnology-based approaches, is targeting at a nano scale a difficult subject?

    Annals of Translational Medicine, Vol. 5, Núm. 22

  4. Unmet clinical needs in the treatment of systemic fungal infections: The role of amphotericin B and drug targeting

    International Journal of Pharmaceutics

2015

  1. Oral particle uptake and organ targeting drives the activity of amphotericin B nanoparticles

    Molecular Pharmaceutics, Vol. 12, Núm. 2, pp. 420-431

2013

  1. Hemolytic and pharmacokinetic studies of liposomal and particulate amphotericin B formulations

    International Journal of Pharmaceutics, Vol. 447, Núm. 1-2, pp. 38-46

2012

  1. A novel formulation of solubilised amphotericin B designed for ophthalmic use

    International Journal of Pharmaceutics, Vol. 437, Núm. 1-2, pp. 80-82